Hormonal
Tirzepatide treatment (10-15 mg once weekly) significantly improves waist-to-height ratio (WHtR) categories compared to placebo, with 54.7% of participants improving their WHtR category at 72 weeks versus 9.6% on placebo.
If you have obesity or overweight with related health complications, treatment with tirzepatide (10-15 mg weekly) combined with lifestyle changes significantly improves your waist-to-height ratio, a key marker for cardiometabolic risk, far more effectively than placebo. This suggests a substantial reduction in central adiposity.
At Week 72, 54.7% of participants treated with 10 mg or 15 mg tirzepatide improved WHtR categories compared with 9.6% of participants treated with placebo
Why this rating
Based on a Phase 3, double-blind, randomized, placebo-controlled trial (SURMOUNT-1), which is high-quality evidence, though this specific analysis is post-hoc.
Source
Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1
Naveed Sattar et al. · Journal of Endocrinological Investigation · 2026
DOI 10.1007/s40618-026-02883-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →